OVERVIEW

The problem is that Mental Disorders are on the rise and there is limited science behind “medical” cannabinoid products.

Global cost – mental disorders will cost the global economy $16 trillion by 2030¹
Mental health ailments – 1 in 5 North Americans has some type of mental health condition^2,3,4
Limited science-backed cannabinoid natural plant solutions – to treat mental Illnesses (alternative to opioids)
Cannabinoid medicine – physicians have a difficult time prescribing precise doses
Neurological treatment limitations – cannabidiol (CBD) by itself does not effectively cross the blood-brain barrier
Only one CBD pharmaceutical drug on the market – approved by the US-FDA – to treat epileptic neurological conditions – Epidiolex®, developed by former GW Pharma

CanaQuest has a solution.

Game Changing Formulations – IP protected, International Patents Filed

• Drug candidate, Rx CQ-001, supported by (CBD molecules + formula) – molecules bond and synergistically attach to PPAR receptor allowing Rx CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this.

Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience. Oct. 2020. 

• Drug candidate, Rx CQ-002, supported by (THC molecules + formula) – is a safer alternative to all other THC products. Pre-clinical trials demonstrated reversal of depression-like and schizophrenia related symptoms, complete blockage of memory impairment, hyperactive activity, and gene vulnerability.

Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience Oct. 2020 & International Journal of Molecular Sciences July 2021. 

1) Psychiatric Times, November 2018
2) Open Minds, May 13, 2020
3) Mental Health Commission of Canada
4) National Alliance on Mental Illness (NAMI)